Boston-based Dana-Farber Cancer Institute, Boston Children’s Hospital and Broad Clinical Labs have partnered to launch a research initiative aimed at developing and disseminating clinical molecular testing assays for pediatric cancers.
Each member of the Boston Research in Innovative Genomics for Hematologic and Tumor Sequencing, also called BrightSeq, will play a key role in assay development, validation and deployment, according to an August 6 news release from Dana-Farber.
“By harnessing the complementary expertise of three world-renowned institutions, this initiative aims to simultaneously improve patient care through the return of actionable genomic findings and accelerate pediatric cancer research through robust sample acquisition and correlative molecular analysis,” the release said.
Leave a Reply